SCHEMBL2338020

SCHEMBL2338020

Cc1csc(Nc2ncccc2OCc2cccc(OCC(=O)OC(C)(C)C)c2)n1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCK P35557 18/20 0.71
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
GRM5 P41594 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2361365 0.89 GCK (0.76) GCKALDH1A1RAB9AGRM5
SCHEMBL2337266 0.87 GCK (0.68) GCKALDH1A1RAB9AGRM5
Trifluoroacetic Acid SCHEMBL2337257 0.86 GCK (0.69) GCKALDH1A1RAB9AGRM5
SCHEMBL9072626 0.85 GCK (0.69) GCKALDH1A1RAB9AGRM5
Hydrochloric Acid SCHEMBL2338979 0.84 GCK (0.68) GCKALDH1A1RAB9AGRM5
SCHEMBL2338014 0.84 GCK (0.70) GCKALDH1A1RAB9AGRM5
SCHEMBL12448005 0.83 GCK (1.00) GCKALDH1A1RAB9AGRM5
SCHEMBL2669311 0.83 GCK (0.66) GCKALDH1A1
SCHEMBL2669323 0.83 GCK (0.66) GCKALDH1A1RAB9AGRM5
Hydrochloric Acid SCHEMBL2342431 0.82 GCK (0.98) GCKALDH1A1RAB9AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933077-B2 Glucokinase activators ARRAY BIOPHARMA INC. (US) 2015-01-13 US disclosed
US-8933077-B2 Glucokinase activators ARRAY BIOPHARMA INC. (US) 2015-01-13 US disclosed
US-8933077-B2 Glucokinase activators ARRAY BIOPHARMA INC. (US) 2015-01-13 US disclosed
EP-1948652-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2011-08-24 EP disclosed
EP-1948652-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2011-08-24 EP disclosed
US-20100056530-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2010-03-04 US disclosed
US-20100056530-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2010-03-04 US disclosed
US-20100056530-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2010-03-04 US disclosed
EP-1948652-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-07-30 EP disclosed
WO-2007053345-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-05-10 WO disclosed
WO-2007053345-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056530-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885ALDH1A1 1377/4885RAB9A 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.